Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.85 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | RAF1 | P04049 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31155026 | 0.93 | KRAS (0.73) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL25079020 | 0.93 | KRAS (0.88) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL31154856 | 0.93 | KRAS (0.83) | KRASMAPK3MAPK1 | |
| SCHEMBL25404089 | 0.92 | KRAS (0.87) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL27243454 | 0.92 | KRAS (0.87) | KRASMAPK3MAPK1RAF1 | |
| Mrtx-1133 SCHEMBL25381671 | 0.92 | KRAS (1.00) | KRASMAPK3MAPK1RAF1 | |
| Mrtx-1133 SCHEMBL23053403 | 0.92 | KRAS (1.00) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL29049539 | 0.92 | KRAS (0.80) | KRASMAPK3MAPK1RAF1 | |
| Mrtx-1133 SCHEMBL30437753 | 0.92 | KRAS (1.00) | KRASMAPK3MAPK1RAF1 | |
| Mrtx-1133 SCHEMBL30311229 | 0.92 | KRAS (1.00) | KRASMAPK3MAPK1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300980-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | SHANGHAI KECHOW PHARMA, INC. (CN) | 2024-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300980-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | KRAS, NRAS, HRAS | KRAS 1/4885MAPK3 188/4885MAPK1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.